Ulcerative Colitis Therapeutics Market
Ulcerative Colitis Therapeutics Market Analysis By Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis), By Route of Administration (Oral, Injectables) & By Region - Global Market Insights 2021-2027
Analysis of Ulcerative Colitis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ulcerative Colitis Therapeutics Market Outlook (2021-2027)
The global ulcerative colitis therapeutics market is anticipated to rise at a CAGR of 5.1% from 2021 to 2027. In 2020, revenue from ulcerative colitis therapeutics was US$ 5.6 Bn, which is expected to reach US$ 7.9 Bn by 2027.
|
Report Attributes |
Details |
|
Market Size (2020) |
US$ 5.6 Bn |
|
Projected Year Value (2027) |
US$ 7.9 Bn |
|
Global Market Growth Rate (2021-2027) |
5.1% CAGR |
|
China Market Growth Rate (2021-2027) |
4.8% |
|
Key Companies Profiled |
|
The ulcerative proctitis segment is projected to increase at a 4.7% CAGR from 2021 to 2027.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Ulcerative Colitis Therapeutics from 2017-2020 Vs Market Outlook for 2021-2027
“Increasing Prevalence of Ulcerative Colitis to Fuel Market Revenue”
The global market for ulcerative colitis therapeutics was valued at US$ 5.6 Bn in 2020.
Ulcerative colitis is a type of inflammatory bowel disease that affects a large number of people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis.
Ulcerative colitis can strike anyone at any age; however, it is most frequent in persons aged 15 to 30. The symptoms of ulcerative colitis differ from person to person, but they may include diarrhea, blood in the stool, and immunological response in the abdomen.
Abdominal cramping, nausea, fever, skin ulcers, loss of appetite, weight loss, joint pain, and weariness are all signs of ulcerative colitis. Hemorrhage, colon rupture, and the development of colon cancer are all serious complications of ulcerative colitis.
Around 20% of persons with ulcerative colitis or Crohn's disease, which is also a kind of IBD, have a family relative who has the condition. There is currently no cure for ulcerative colitis. However, some treatments can help to lessen the signs and symptoms of ulcerative colitis and perhaps bring about long-term remission.
Due to an increase in the frequency of ulcerative colitis and increased research and development to produce revolutionary ulcerative colitis treatments, the global ulcerative colitis therapeutics market is predicted to grow significantly.
All of these factors are expected to drive the market at 5.1% CAGR from 2021 to 2027.
Which Key Market Contributors are Driving Demand for Ulcerative Colitis Therapeutics?
“Continuous Advancements in Novel Treatments Boosting Market Growth”
The existence of enhanced ulcerative colitis therapies as a result of recent advancements, as well as the growing patient pool in need of treatment, are two main catalytic drivers driving the ulcerative colitis market forward.
Increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are all contributing to the industry growth.
Due to increased demand for ulcerative colitis therapeutic drugs, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.
Increased research and development efforts by public and private healthcare institutions are likely to increase opportunities for ulcerative colitis market participants.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What are the Challenging Factors for Market Expansion?
“Unfavorable Legislations & Expiration of Drug Patents Hampering Market Value Growth”
The market for ulcerative colitis therapeutics is projected to be constrained by the expiration of drug patents and strict government norms and regulations for biosimilar licensing. The market is additionally hampered by unfavorable legislation and policies, as well as varying circumstances in different nations.
Lack of understanding of the disease, and significant limitations of existing therapy choices could all operate as roadblocks for ulcerative colitis therapeutic solutions providers.
Which Region Dominates the Global Ulcerative Colitis Therapeutics Market?
“Rising Demand for Advanced Medical Technologies Driving Industry Growth in North America”
North America is likely to lead the ulcerative colitis therapeutics market because of the presence of prominent players and the rising frequency of ulcerative colitis in the region, as well as continued financing for the discovery of new therapies for the treatment of diseases.
The market is growing due to the rising demand for novel medical technologies and the presence of adequate medical facilities.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Why is the U.S. an Important Market for Ulcerative Colitis Therapeutic Drug Providers?
“High Availability of Treatment Choices Stimulating Market Expansion”
The U.S. ulcerative colitis therapeutics market was valued at US$ 1.7 Bn in 2020 and is projected to increase at the highest CAGR over the forecast period. In the United States, ulcerative colitis affects between 250,000 and 500,000 people, with an annual incidence of 8 to 12 per 100,000 people that has been stable over the last five decades.
The market is expected to grow significantly over the projected period due to wide availability of treatment choices, high healthcare spending, prevalence of diagnostic techniques that lead to early disease diagnosis, and an established healthcare system.
What is the Outlook for the China Ulcerative Colitis Therapeutics Market?
“Significant Healthcare Expenditure by Government Entities to Boost Market Value”
The market in China is expected to reach a valuation of US$ 1.4 Bn by 2027, representing a 4.8% CAGR from 2021 to 2027. The market in China is expected to be highly attractive over the forecast period, due to increased product approvals and high disposable income.
Market growth is being driven by a growing focus on developing healthcare facilities, economic growth, enhanced healthcare services, and the government's supportive policies.
Category-wise Insights
Which Disease Type Shows the Highest Potential for Ulcerative Colitis Therapeutics?
“Innovative Therapeutics for Ulcerative Proctitis Driving Market Revenue”
The ulcerative proctitis segment is projected to record a 4.7% CAGR and reach US$ 2.1 Bn over the forecast period. One of the types of ulcerative colitis is ulcerative proctitis. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative proctitis.
The segment is expected to grow due to increased research & development initiatives in the discovery of innovative therapeutics for ulcerative proctitis. Market revenue is being boosted by a growth in the number of inflammatory bowel diseases, ulcerative proctitis diseases, and the development of new ulcerative proctitis medications in clinical laboratories.
Which Route of Administration Enjoys High Preference?
“Oral Route of Administration More Preferred Owing to Strong Presence of Oral Pipeline Products”
The oral route of administration is expected to grow at the fastest rate over the forecast period. The approval of innovative medications for the treatment of ulcerative colitis, as well as the strong presence of oral pipeline products for the treatment of ulcerative colitis, have contributed to the segment growth.
Because of increased R&D efforts in the pharmaceutical and medical device industries, increased demand for pharmaceuticals required for treatment, and increased use of various types of ulcerative colitis drugs, the oral route of administration segment is expected to grow significantly.
COVID-19 Impact on Sales of Ulcerative Colitis Therapeutic Medications
The COVID-19 pandemic negatively impacted the ulcerative colitis therapeutics market. Outpatient visits, optional surgeries, and international patients all dropped sharply in the healthcare industry. As a result of the delayed procedures for ulcerative colitis treatment, the production of drugs for ulcerative colitis disease dropped.
Key companies working strategically in the clinical stage of development for ulcerative colitis will lead to a significant increase in market size over the forecast period. Rising advances in ulcerative colitis treatment, the emergence of biosimilars, and increasing drug approvals & launches are expected to drive the market growth over the coming years.
Competitive Landscape
The market for ulcerative colitis therapeutics is highly competitive. Certain strategic efforts, such as mergers, new product launches, acquisitions, and collaborations, are implemented by key players to help them increase their market position.
For instance :
- In May 2021, The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Zeposia (ozanimod) for the treatment of individuals with moderately to highly active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Key Segments Covered in Ulcerative Colitis Therapeutics Industry Research
-
By Disease Type :
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
-
By Route of Administration :
- Oral
- Injectables
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Product USPs /Technology 4.4. List of manufacturers and providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New product launches 5.2.2. Cost of products 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1.1. Current COVID19 Statistics and Probable Future Impact 6.1.2. Current GDP Projection and Probable Impact 6.1.3. Current Economic Projection as Compared to 2008 Economic analysis 6.1.4. COVID19 and Impact Analysis 6.1.4.1. Revenue By Disease Type 6.1.4.2. Revenue By Route of Administration 6.1.4.3. Revenue By Country 6.1.5. 2020 Market Scenario 6.1.6. Quarter by Quarter Forecast 6.1.7. Projected Recovery Quarter 7. Global Ulcerative Colitis Therapeutics Market Volume (Units) Analysis 2017-2020 and Forecast, 2021-2027 7.1. Historical Market Volume (Units) Analysis, 2017-2020 7.2. Current and Future Market Volume (Units) Projections, 2021-2027 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Ulcerative Colitis Therapeutics Market - Pricing Analysis 8.1. Regional Pricing Analysis By Disease Type 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Ulcerative Colitis Therapeutics Market Value Analysis 2017–2020 and Forecast, 2021-2027 9.1. Historical Market Value (US$ Mn) Analysis, 2017–2020 9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2027 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027, by Disease Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2017–2020 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2021-2027 10.3.1. Ulcerative Proctitis 10.3.2. Proctosigmoiditis 10.3.3. Left-sided Colitis 10.3.4. Pancolitis or Universal Colitis 10.3.5. Fulminant Colitis 10.4. Market Attractiveness Analysis By Disease Type 11. Global Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027, by Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration , 2017–2020 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration , 2021-2027 11.3.1. Oral 11.3.2. Injectables 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2020 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2027 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Disease Type 13.3.3. By Route of Administration 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Disease Type 14.3.3. By Route of Administration 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Disease Type 15.3.3. By Route of Administration 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Disease Type 16.3.3. By Route of Administration 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Disease Type 17.3.3. By Route of Administration 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Disease Type 18.3.3. By Route of Administration 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2020 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2027 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Disease Type 19.3.3. By Route of Administration 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Ulcerative Colitis Therapeutics Market Analysis 2017–2020 and Forecast 2021-2027 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Ulcerative Colitis Therapeutics Market Analysis 20.2.1. By Disease Type 20.2.2. By Route of Administration 20.3. Canada Ulcerative Colitis Therapeutics Market Analysis 20.3.1. By Disease Type 20.3.2. By Route of Administration 20.4. Mexico Ulcerative Colitis Therapeutics Market Analysis 20.4.1. By Disease Type 20.4.2. By Route of Administration 20.5. Brazil Ulcerative Colitis Therapeutics Market Analysis 20.5.1. By Disease Type 20.5.2. By Route of Administration 20.6. U.K. Ulcerative Colitis Therapeutics Market Analysis 20.6.1. By Disease Type 20.6.2. By Route of Administration 20.7. Germany Ulcerative Colitis Therapeutics Market Analysis 20.7.1. By Disease Type 20.7.2. By Route of Administration 20.8. France Ulcerative Colitis Therapeutics Market Analysis 20.8.1. By Disease Type 20.8.2. By Route of Administration 20.9. Italy Ulcerative Colitis Therapeutics Market Analysis 20.9.1. By Disease Type 20.9.2. By Route of Administration 20.10. Spain Ulcerative Colitis Therapeutics Market Analysis 20.10.1. By Disease Type 20.10.2. By Route of Administration 20.11. BENELUX Ulcerative Colitis Therapeutics Market Analysis 20.11.1. By Disease Type 20.11.2. By Route of Administration 20.12. Russia Ulcerative Colitis Therapeutics Market Analysis 20.12.1. By Disease Type 20.12.2. By Route of Administration 20.13. China Ulcerative Colitis Therapeutics Market Analysis 20.13.1. By Disease Type 20.13.2. By Route of Administration 20.14. Japan Ulcerative Colitis Therapeutics Market Analysis 20.14.1. By Disease Type 20.14.2. By Route of Administration 20.15. South Korea Ulcerative Colitis Therapeutics Market Analysis 20.15.1. By Disease Type 20.15.2. By Route of Administration 20.16. India Ulcerative Colitis Therapeutics Market Analysis 20.16.1. By Disease Type 20.16.2. By Route of Administration 20.17. ASEAN Ulcerative Colitis Therapeutics Market Analysis 20.17.1. By Disease Type 20.17.2. By Route of Administration 20.18. Australia Ulcerative Colitis Therapeutics Market Analysis 20.18.1. By Disease Type 20.18.2. By Route of Administration 20.19. New Zealand Ulcerative Colitis Therapeutics Market Analysis 20.19.1. By Disease Type 20.19.2. By Route of Administration 20.20. GCC Countries Ulcerative Colitis Therapeutics Market Analysis 20.20.1. By Disease Type 20.20.2. By Route of Administration 20.21. Turkey Ulcerative Colitis Therapeutics Market Analysis 20.21.1. By Disease Type 20.21.2. By Route of Administration 20.22. South Africa Ulcerative Colitis Therapeutics Market Analysis 20.22.1. By Disease Type 20.22.2. By Route of Administration 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Abbott Laboratories, Inc. 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.1.5.1. Marketing Strategy 22.3.1.5.2. Product Strategy 22.3.1.5.3. Channel Strategy 22.3.2. AstraZeneca PLC 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.2.5.1. Marketing Strategy 22.3.2.5.2. Product Strategy 22.3.2.5.3. Channel Strategy 22.3.3. Avaxia Biologics, Inc. 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.3.5.1. Marketing Strategy 22.3.3.5.2. Product Strategy 22.3.3.5.3. Channel Strategy 22.3.4. BioLineRx Ltd. 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.4.5.1. Marketing Strategy 22.3.4.5.2. Product Strategy 22.3.4.5.3. Channel Strategy 22.3.5. Astellas Pharma, Inc. 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.5.5.1. Marketing Strategy 22.3.5.5.2. Product Strategy 22.3.5.5.3. Channel Strategy 22.3.6. Cosmo Pharmaceuticals NV 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.6.5.1. Marketing Strategy 22.3.6.5.2. Product Strategy 22.3.6.5.3. Channel Strategy 22.3.7. AbbVie, Inc. 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Profitability by Market Segments (Product/Channel/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Strategy Overview 22.3.7.5.1. Marketing Strategy 22.3.7.5.2. Product Strategy 22.3.7.5.3. Channel Strategy 22.3.8. Amgen, Inc. 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Profitability by Market Segments (Product/Channel/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Strategy Overview 22.3.8.5.1. Marketing Strategy 22.3.8.5.2. Product Strategy 22.3.8.5.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Ulcerative Colitis Therapeutics Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 02: Global Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 03: Global Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 04: Global Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Region
Table 05: North America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 06: North America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 07: North America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 08: Latin America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 09: Latin America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 10: Latin America Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 11: Europe Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 12: Europe Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 13: Europe Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 14: South Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 15: South Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 16: South Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 17: East Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 18: East Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 19: East Asia Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 20: Oceania Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 21: Oceania Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 22: Oceania Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
Table 23: Middle East and Africa Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis 2017-2020 and Forecast 2021–2027, By Country
Table 24: Middle East and Africa Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Disease Type
Table 25: Middle East and Africa Ulcerative Colitis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2027, By Route of Administration
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Ulcerative Colitis Therapeutics Market Volume (in 000' Units) Analysis, 2017-2020
Figure 02: Global Ulcerative Colitis Therapeutics Market Volume Forecast (in 000' Units), 2021-2027
Figure 03: Ulcerative Colitis Therapeutics Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Ulcerative Colitis Therapeutics Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 06: Global Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 07: Global Ulcerative Colitis Therapeutics Market Absolute $ Opportunity, 2021-2027
Figure 08: Global Ulcerative Colitis Therapeutics Market Share Analysis (%), By Disease Type, 2021-2027
Figure 09: Global Ulcerative Colitis Therapeutics Market Y-o-Y Analysis (%), By Disease Type, 2021-2027
Figure 10: Global Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 11: Global Ulcerative Colitis Therapeutics Market Share Analysis (%), By Route of Administration, 2021-2027
Figure 12: Global Ulcerative Colitis Therapeutics Market Y-o-Y Analysis (%), By Route of Administration, 2021-2027
Figure 13: Global Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 14: Global Ulcerative Colitis Therapeutics Market Share Analysis (%), By Region, 2021-2027
Figure 15: Global Ulcerative Colitis Therapeutics Market Y-o-Y Analysis (%), By Region, 2021-2027
Figure 16: Global Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Region, 2021-2027
Figure 17: North America Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 18: North America Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 19: North America Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 20: North America Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 21: North America Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 22: North America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 23: North America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 24: North America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 25: Latin America Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 26: Latin America Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 27: Latin America Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 28: Latin America Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 29: Latin America Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 30: Latin America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 31: Latin America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 32: Latin America Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 33: Europe Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 34: Europe Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 35: Europe Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 36: Europe Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 37: Europe Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 38: Europe Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 39: Europe Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 40: Europe Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 41: South Asia Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 42: South Asia Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 43: South Asia Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 44: South Asia Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 45: South Asia Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 46: South Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 47: South Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 48: South Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 49: East Asia Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 50: East Asia Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 51: East Asia Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 52: East Asia Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 53: East Asia Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 54: East Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 55: East Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 56: East Asia Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 57: Oceania Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 58: Oceania Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 59: Oceania Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 60: Oceania Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 61: Oceania Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 62: Oceania Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 63: Oceania Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 64: Oceania Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 65: Middle East and Africa Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 66: Middle East and Africa Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 67: Middle East and Africa Ulcerative Colitis Therapeutics Market Value Share, By Country, 2021 (E)
Figure 68: Middle East and Africa Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2017-2020
Figure 69: Middle East and Africa Ulcerative Colitis Therapeutics Market Value Forecast (US$ Mn), 2021-2027
Figure 70: Middle East and Africa Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Disease Type, 2021-2027
Figure 71: Middle East and Africa Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Route of Administration, 2021-2027
Figure 72: Middle East and Africa Ulcerative Colitis Therapeutics Market Attractiveness Analysis by Country, 2021-2027
Figure 73: U. S. Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 74: U. S. Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 75: U. S. Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 76: Canada Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 77: Canada Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 78: Canada Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 79: Mexico Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 80: Mexico Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 81: Mexico Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 82: Brazil Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 83: Brazil Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 84: Brazil Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 85: U. K. Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 86: U. K. Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 87: U. K. Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 88: Germany Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 89: Germany Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 90: Germany Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 91: France Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 92: France Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 93: France Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 94: Italy Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 95: Italy Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 96: Italy Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 97: Spain Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 98: Spain Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 99: Spain Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 100: Russia Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 101: Russia Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 102: Russia Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 103: China Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 104: China Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 105: China Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 106: Japan Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 107: Japan Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 108: Japan Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 109: South Korea Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 110: South Korea Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 111: South Korea Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 112: India Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 113: India Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 114: India Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 115: ASEAN Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 116: ASEAN Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 117: ASEAN Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 118: Australia Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 119: Australia Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 120: Australia Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 121: New Zealand Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 122: New Zealand Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 123: New Zealand Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 124: GCC Countries Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 125: GCC Countries Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 126: GCC Countries Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 127: Turkey Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 128: Turkey Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 129: Turkey Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Figure 130: South Africa Ulcerative Colitis Therapeutics Market Value Analysis (US$ Mn), 2021 & 2027
Figure 131: South Africa Ulcerative Colitis Therapeutics Market Value Share, By Disease Type, 2021 (E)
Figure 132: South Africa Ulcerative Colitis Therapeutics Market Value Share, By Route of Administration, 2021 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the total market worth of ulcerative colitis therapeutics in 2021?
The global ulcerative colitis therapeutics market reached a valuation of US$ 5.86 Bn in 2021.
What is the anticipated CAGR of the global ulcerative colitis therapeutics market over the forecast period?
The global ulcerative colitis therapeutics market is estimated to expand at a CAGR of 5.1% from 2021 to 2027.
Who are the key providers of ulcerative colitis therapeutic products?
Abbott Laboratories, Inc., AstraZeneca PLC, Avaxia Biologics, Inc., BioLineRx Ltd., and Astellas Pharma, Inc. are key providers of ulcerative colitis therapeutic products.
Which are the top 5 countries driving demand for ulcerative colitis therapeutics?
The U.S., Canada, Germany, Japan, and China are expected to drive most demand for ulcerative colitis therapeutics.
What is the sales forecast for ulcerative colitis therapeutics?
The global market for ulcerative colitis therapeutics is expected to be valued at US$ 7.9 Bn by 2027.
Which growth trends are driving global demand ulcerative colitis therapeutic solutions?
High global incidence and prevalence of ulcerative colitis, technological advancements, and increase in patient assistance programs are driving market growth.
Ulcerative Colitis Therapeutics Market